You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

192 search results for: type 2 inflammation

expert video

Practical Considerations for the Management of Children With Moderate-to-severe Atopic Dermatitis

26 min

Dermatology

Highlights from the 2023 WCD ADVENT symposium, exploring practical considerations for the management of atopic dermatitis in children.

expert video

Targeted Therapies for Children With Atopic Dermatitis - Expert Interview

9 min

Dermatology

Dermatologist Elaine Seigfried discusses burden & therapeutic landscape of pediatric atopic dermatitis

expert video

Challenges Faced by Dermatologists When Managing Atopic Dermatitis in Children - Expert Interview (Copy)

8 min

Dermatology

Watch ADVENT now: Dermatologist Mark Koh describes the Challenges Faced by Dermatologists When Managing Atopic Dermatitis in Children.

expert video

ESPGHAN 2024 | Burden and Timely Recognition of Pediatric EoE

13 min

Gastroenterology

Dr. Dhandapani Ashok discusses patient and caregiver burden in pediatric EoE and the challenges with identifying EoE in a young patient population.

UCARE <b>2</b>0<b>2</b>3: CSU – The Brazil Perspective

expert video

UCARE 2023: CSU – The Brazil Perspective

6 min

Dermatology

Dr. Ensina guides discussions on the perspective of CSU management in Brazil.

expert video

Managing the Risk of Fibrostenosis in EoE

2 min

Gastroenterology

Hear from Drs. Jason Lee, Kathryn Peterson, Seema Aceves, and Ikuo Hirano on disease progression and the importance of managing fibrostenotic risk in EoE.

UCARE <b>2</b>0<b>2</b>3: Non-Histaminergic Neuronal Sensitization in CSU

expert video

UCARE 2023: Non-Histaminergic Neuronal Sensitization in CSU

1 min

Dermatology

Dr. Kim highlights the role of non-histaminergic neuronal sensitization in CSU via cytokines.

expert video

EAACI 2022 | Hard to Swallow: Identifying and Managing EoE in the Allergy Clinic

21 min

Gastroenterology

Experts Prof. Ingrid Terreehorst and Prof. Arjan Bredenoord discuss the allergist’s perspective on identifying and management of patients with EoE.

UCARE <b>2</b>0<b>2</b>3: Emerging Clinical Trial Data in CSU

expert video

UCARE 2023: Emerging Clinical Trial Data in CSU

13 min

Dermatology

Dr. Maurer explores current clinical data from leading emerging therapies in CSU.

UCARE <b>2</b>0<b>2</b>3: Implications of Different Modes of Action of Dupilumab, Remibrutinib, and Barzolvolimab

expert video

UCARE 2023: Implications of Different Modes of Action of Dupilumab, Remibrutinib, and Barzolvolimab

1 min

Dermatology

Dr. Maurer summarises the implications of different modes of action of dupilumab, remibrutinib and barzolvolimab.

expert video

Skin Dysbiosis in AD

17 min

Dermatology

Dr. Lisa Beck discusses how S. aureus colonization contributes to a disrupted skin microbiome, skin barrier dysfunction, disease flares and increased disease severity in AD, and how blocking IL-4 and IL-13 can reduce S. aureus colonization.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: SwedenChange country/region